Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Press Releases

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Press Releases

Company News

Date Title and Summary Additional Formats
Toggle Summary May 16, 2022 Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , May 16, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company focused on
View HTML
PDF Version
Toggle Summary May 10, 2022 Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022 FDA Allows GEN-1 + Avastin Phase II study LAWRENCEVILLE, N.J. , May 10, 2022 (GLOBE NEWSWIRE) -- Celsion
View HTML
PDF Version
Toggle Summary May 9, 2022 Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
LAWRENCEVILLE, N.J. , May 09, 2022 (GLOBE NEWSWIRE) -- Celsion   Corporation  (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.
View HTML
PDF Version
Toggle Summary Apr 21, 2022 Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible Platform Appears to Show Promise LAWRENCEVILLE, N.J. , April 21, 2022 (GLOBE NEWSWIRE) -- Celsion
View HTML
PDF Version
Toggle Summary Apr 14, 2022 Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
  Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well   received at 2022 AACR A nnual M eeti ng LAWRENCEVILLE, N.J. , April 14, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) a clinical-stage company focused on DNA-based immunotherapy and
View HTML
PDF Version
Toggle Summary Apr 12, 2022 Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
LAWRENCEVILLE, N.J. , April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine
View HTML
PDF Version
Toggle Summary Apr 8, 2022 Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
LAWRENCEVILLE, NJ , April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, of 1,328,274 shares of common stock at a purchase
View HTML
PDF Version
Toggle Summary Apr 6, 2022 Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J. , April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) a clinical-stage company
View HTML
PDF Version
Toggle Summary Apr 6, 2022 CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ , April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price
View HTML
PDF Version
Toggle Summary Apr 1, 2022 Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
LAWRENCEVILLE, N.J. , April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings
View HTML
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • LinkedIn
    • Twitter
    • RSS

Celsion
Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

LinkedIn

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2022 Celsion Corporation. All rights reserved.

    • Twitter
    • Facebook
    • LinkedIn
    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn